Development and Characterization of siRNA Lipoplexes: Effect of Different Lipids, In Vitro Evaluation in Cancerous Cell Lines and In Vivo Toxicity Study

Ageing International

Volumn 15, Issue 6, 2014, Pages 1630-1643

  Khatri, Nirav ^a   Baradia, Dipesh ^a   Vhora, Imran ^a   Rathi, Mohan ^a   Misra, Ambikanandan ^a  

^a M S UNIVERSITY OF BARODA   (India)

Author keywords

cancer; gene expression; lipoplex; siRNA; toxicity

Indexed keywords

LIPID; LIPOSOME; RRM1 PROTEIN, HUMAN; SMALL INTERFERING RNA; TUMOR SUPPRESSOR PROTEIN;

ANIMAL; BLOOD; CELL SURVIVAL; CHEMISTRY; COMPARATIVE STUDY; DRUG EFFECTS; FEMALE; GENE EXPRESSION REGULATION; GENE THERAPY; GENETIC TRANSFECTION; GENETICS; HEMOLYSIS; HUMAN; METABOLISM; MOUSE; NEOPLASMS; PARTICLE SIZE; PATHOLOGY; PROCEDURES; RNA INTERFERENCE; RNA STABILITY; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CELL SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC THERAPY; HEMOLYSIS; HUMANS; LIPIDS; LIPOSOMES; MICE; NEOPLASMS; PARTICLE SIZE; RNA INTERFERENCE; RNA STABILITY; RNA, SMALL INTERFERING; TRANSFECTION; TUMOR SUPPRESSOR PROTEINS;

EID: 84911996486     PISSN: 01635158     EISSN: 1936606X     Source Type: Journal    
DOI: 10.1208/s12249-014-0193-9     Document Type: Article

References (39)

1. Lung cancer incidence and mortality worldwide in 2008 GLOBACON 2008 (IARC), Section of Cancer Information. 2008.
2. Horn L, Pao W, Johnson DH. Neoplasms of the lung. In: Longo D, Fauci A, Kasper D, Hauser S, Jameson J, Loscalzo J, editors. Harrison’s principles of internal medicine. 18th ed. United States: McGraw-Hill; 2011.
3. Thun MJ, Hannan LM, Adams-Campbell LL, Boffetta P, Buring JE, Feskanich D, et al. Lung cancer occurrence in never-smokers: an analysis of 13 cohorts and 22 cancer registry studies. PLoS Med. 2008;5(9):e185. doi:10.1371/journal.pmed.0050185.
4. Tsao AS. Tumors of the lungs. In: Porter RS, Kaplan JL, editors. The merck manual—fot the healthcare professionals. US: MERCK PUBLISHING GROUP; 2010.
5. Rha SY, Jeung HC, Choi YH, Yang WI, Yoo JH, Kim BS, et al. An association between RRM1 haplotype and gemcitabine-induced neutropenia in breast cancer patients. Oncologist. 2007;12(6):622–30. doi:10.1634/theoncologist.12-6-622.
6. Rosell R, Danenberg KD, Alberola V, Bepler G, Sanchez JJ, Camps C, et al. Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res Off J Am Assoc Cancer Res. 2004;10(4):1318–25.
7. Khatri N, Rathi M, Baradia D, Trehan S, Misra A. In vivo delivery aspects of miRNA, shRNA and siRNA. Crit Rev Ther Drug Carrier Syst. 2012;29(6):487–527.
8. Mah C, Byrne BJ, Flotte TR. Virus-based gene delivery systems. Clin Pharmacokinet. 2002;41(12):901–11. doi:10.2165/00003088-200241120-00001.
9. Strayer DS. Viral gene delivery. Expert Opin Investig Drugs. 1999;8(12):2159–72. doi:10.1517/13543784.8.12.2159.
10. Khatri NI, Rathi MN, Kolte AA, Kore GG, Lalan MS, Trehan S, et al. Patents review in siRNA delivery for pulmonary disorders. Recent Patents Drug Deliv Formul. 2012;6(1):45–65.
11. Khatri N, Baradia D, Vhora I, Rathi M, Misra A. cRGD grafted liposomes containing inorganic nano-precipitate complexed siRNA for intracellular delivery in cancer cells. J Control Release. 2014;182:45–57. doi:10.1016/j.jconrel.2014.03.003.
12. Oku N, Namba Y. Glucuronate-modified, long-circulating liposomes for the delivery of anticancer agents. Methods Enzymol. 2005;391:145–62. doi:10.1016/s0076-6879(05)91008-2.
13. van Winden ECA, Crommelin DJA. Long term stability of freeze-dried, lyoprotected doxorubicin liposomes. Eur J Pharm Biopharm. 1997;43(3):295–307. doi:10.1016/S0939-6411(97)00058-1.
14. OECD guideline for testing of chemicals, OECD Test Guideline 420: acute oral toxicity—fixed dose procedure. OECD Publishing, Organization for Economic Co-operation and Development; 2008.
15. Drummond DC, Meyer O, Hong K, Kirpotin DB, Papahadjopoulos D. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev. 1999;51(4):691–744.
16. Sułkowski WW, Pentak D, Nowak K, Sułkowska A. The influence of temperature, cholesterol content and pH on liposome stability. J Mol Struct. 2005;744–747:737–47. doi:10.1016/j.molstruc.2004.11.075.
17. De Gier J, Mandersloot JG, Van Deenen LLM. Lipid composition and permeability of liposomes. Biochim Biophys Acta Biomembr. 1968;150(4):666–75. doi:10.1016/0005-2736(68)90056-4.
18. van der Woude I, Visser HW, ter Beest MB, Wagenaar A, Ruiters MH, Engberts JB, et al. Parameters influencing the introduction of plasmid DNA into cells by the use of synthetic amphiphiles as a carrier system. Biochim Biophys Acta. 1995;1240(1):34–40.
19. Zelphati O, Szoka FC. Mechanism of oligonucleotide release from cationic liposomes. Proc Natl Acad Sci. 1996;93(21):11493–8.
20. Bhattacharya S, Haldar S. The effects of cholesterol inclusion on the vesicular membranes of cationic lipids. Biochim Biophys Acta. 1996;1283(1):21–30.
21. Bhattacharya S, Haldar S. Interactions between cholesterol and lipids in bilayer membranes. Role of lipid headgroup and hydrocarbon chain-backbone linkage. Biochim Biophys Acta. 2000;1467(1):39–53.
22. Fang J, Nakamura H, Maeda H. The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev. 2011;63(3):136–51. doi:10.1016/j.addr.2010.04.009.
23. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release Off J Control Release Soc. 2000;65(1–2):271–84.
24. Zhang Y, Yang M, Park JH, Singelyn J, Ma H, Sailor MJ, et al. A surface-charge study on cellular-uptake behavior of F3-peptide-conjugated iron oxide nanoparticles. Small (Weinheim Bergstrasse Germany). 2009;5(17):1990–6. doi:10.1002/smll.200900520.
25. Zhang Y, Yang M, Portney NG, Cui D, Budak G, Ozbay E, et al. Zeta potential: a surface electrical characteristic to probe the interaction of nanoparticles with normal and cancer human breast epithelial cells. Biomed Microdevices. 2008;10(2):321–8. doi:10.1007/s10544-007-9139-2.
26. Haupenthal J, Baehr C, Kiermayer S, Zeuzem S, Piiper A. Inhibition of RNAse A family enzymes prevents degradation and loss of silencing activity of siRNAs in serum. Biochem Pharmacol. 2006;71(5):702–10. doi:10.1016/j.bcp.2005.11.015.
27. Subramanian N, Murthy RS. Use of electrolyte induced flocculation technique for an in vitro steric stability study of steric stabilized liposome formulations. Die Pharm. 2004;59(1):74–6.
28. Lu JJ, Langer R, Chen J. A novel mechanism is involved in cationic lipid-mediated functional siRNA delivery. Mol Pharm. 2009;6(3):763–71. doi:10.1021/mp900023v.
29. Takahashi T, Kono K, Itoh T, Emi N, Takagishi T. Synthesis of novel cationic lipids having polyamidoamine dendrons and their transfection activity. Bioconjug Chem. 2003;14(4):764–73. doi:10.1021/bc025663f.
30. Martino S, di Girolamo I, Tiribuzi R, Angelo F, Datti A, et al. Efficient siRNA delivery by the cationic liposome DOTAP in human hematopoietic stem cells differentiating into dendritic cells. J Biomed Biotechnol. 2009;2009. doi: 10.1155/2009/410260.
31. Terp MC, Bauer F, Sugimoto Y, Yu B, Brueggemeier RW, Lee LJ, et al. Differential efficacy of DOTAP enantiomers for siRNA delivery in vitro. Int J Pharm. 2012;430(1–2):328–34. doi:10.1016/j.ijpharm.2012.04.017.
32. Ma Z, Li J, He F, Wilson A, Pitt B, Li S. Cationic lipids enhance siRNA-mediated interferon response in mice. Biochem Biophys Res Commun. 2005;330(3):755–9. doi:10.1016/j.bbrc.2005.03.041.
33. Dominska M, Dykxhoorn DM. Breaking down the barriers: siRNA delivery and endosome escape. J Cell Sci. 2010;123(8):1183–9.
34. Xu Y, Szoka Jr FC. Mechanism of DNA release from cationic liposome/DNA complexes used in cell transfection. Biochemistry. 1996;35(18):5616–23. doi:10.1021/bi9602019.
35. Zhou X, Huang L. DNA transfection mediated by cationic liposomes containing lipopolylysine: characterization and mechanism of action. Biochim Biophys Acta (BBA) Biomembr. 1994;1189(2):195–203. doi:10.1016/0005-2736(94)90066-3.
36. Zuhorn IS, Bakowsky U, Polushkin E, Visser WH, Stuart MC, Engberts JB, et al. Nonbilayer phase of lipoplex-membrane mixture determines endosomal escape of genetic cargo and transfection efficiency. Mol Ther J Am Soc Gene Ther. 2005;11(5):801–10. doi:10.1016/j.ymthe.2004.12.018.
37. Chen C, Han D, Cai C, Tang X. An overview of liposome lyophilization and its future potential. J Control Release Off J Control Release Soc. 2010;142(3):299–311. doi:10.1016/j.jconrel.2009.10.024.
38. Lewis DA, Alpar HO. Erhythrocytes as microvesicles. In: Danbrow M, editor. Microcapsules and nanoparticles in medicine and pharmacy. FL: CRC Press; 1991. p. 299–314.
39. Fildes F. Liposomes: the industrial view point. in: liposomes from physical structure to therapeutic applications. New York: Elsevier Biomedical Press; 1998.